|Videos|January 23, 2020

What is Antiretroviral Stewardship?

Daniel B. Chastain, PharmD, BCIDP, AAHIVP, clinical assistant professor at the University of Georgia College of Pharmacy, explains antiretroviral stewardship.

Segment Description: Daniel B. Chastain, PharmD, BCIDP, AAHIVP, clinical assistant professor at the University of Georgia College of Pharmacy, explains antiretroviral stewardship at IDWeek 2019.

Interview Transcript (modified slightly for readability):

Chastain: I'll put in a plug for paper that was published in CID (Clinical Infectious Diseases), within a week or so ago, that really was a call to action for antiretroviral stewardship.

It's hopefully the next logical step in antimicrobial stewardship as a whole. But antiretroviral stewardship is a little bit different than antimicrobial stewardship in that antiretrovirals are typically started in the outpatient setting and then continued upon inpatient admission.

It's certainly a different aspect, really making sure that patients are compliant, if they are supposedly on antiretrovirals, and also making sure that we have those agents available for them. Whether it's splitting up a single tablet regimen or continuing that single tablet regimen at home, because if we administer them inappropriately, whether it be an incorrect schedule or incorrect regimen doses, for example, it could certainly lead to higher rates of drug interactions, deleterious adverse effects, virologic failure even and forcing them to have to change the regimen later on in the future if they experience resistance.


Related to this article

Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.